A biotech branding brief that does not explain the science is not a brief. It is a decoration request.
Why Biotech Branding Briefs Fail
A biotech branding brief fails when it is written by someone who does not understand what makes biotech branding different from every other category of brand work. The brief is the foundation of everything the studio produces. A brief that omits the science, skips the regulatory context, and does not distinguish between the investor, HCP, and patient audiences is a brief that will produce generic work.
The global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a compound annual growth rate of 13.96%, according to Grand View Research. That growth is generating more biotech companies, more funding rounds, and more branding projects than at any point in the industry's history. Most of those projects start with briefs that treat biotech branding as if it were consumer branding with clinical colors. It is not.
I am a pharmacist and creative director. I have been building life sciences brands for 17 years. The brief is where the outcome is determined. What follows is exactly what a biotech branding brief must include, and what most briefs miss.
What a Biotech Branding Brief Must Include
A complete biotech branding brief covers seven areas. Most briefs cover two or three. The gaps in the brief are the gaps in the work.
1. The Science, Explained for a Non-Scientist
This is the section most briefs omit and the one that matters most. The studio needs to understand what the company actually does well enough to make strategic decisions about how to communicate it. That does not mean a research paper. It means a plain-English explanation of the mechanism of action, the indication or application, and what makes the science different from what competitors are doing.
A studio that does not understand the science will make design decisions based on aesthetic conventions rather than scientific differentiation. The result is a brand that looks like every other company in the category because there was nothing specific enough in the brief to drive a different direction.
What to include:
What does the company do, in two or three sentences a smart person outside the field can follow
What makes the approach scientifically distinctive
What the company does not do or explicitly does not claim (this is often as important as what it does claim for regulatory reasons)
The development stage: pre-clinical, clinical stage, pre-commercial, commercial
2. Audience Prioritization and What Each Audience Needs to Believe
Biotech brands serve multiple simultaneous audiences. Investors need to believe in commercial viability and scientific credibility. Healthcare professionals need to believe in the science and the company's depth. Patients need to believe in safety and the mission. These are different beliefs that require different communication strategies.
A brief that lists "investors, HCPs, and patients" without ranking them and specifying what each needs to believe after brand exposure is a brief that will produce work optimized for no one. Ask yourself: at this stage of the company's development, which audience is most critical, and what does the brand need to make them believe?
According to a 2024 BioPharma Dive analysis, biotech companies with brand identities that clearly prioritized investor communication in their early stages raised subsequent funding rounds at valuations 18% higher than companies with generic visual identities. Audience prioritization is a commercial decision, not a creative one.
3. Competitive Landscape and Differentiation Intent
The brief should include a specific competitive landscape: which companies are the direct competitors, what their brands look like, and where the visual territory is overcrowded or underoccupied. Do not rely on the studio to do this research independently without your input. You know your competitive field. The studio knows visual strategy. The brief is where that knowledge combines.
Include three to five direct competitors with specific notes on their brand positioning and visual identity. Note where you want to be different and, critically, where you want to be legible within the category conventions. Differentiation has limits in a trust-dependent category: being too visually unusual for biotech can undermine credibility. The brief should define where the dial sits between category convention and distinctive differentiation.
4. Regulatory Context by Market
What can and cannot be said about the company and its pipeline in brand communications varies significantly by market and development stage. Pre-clinical companies face different restrictions than clinical-stage companies. FDA, EMA, and other regulatory bodies have specific rules about what can be represented as established versus investigational.
A biotech branding studio that does not ask about this in the brief stage is not accounting for it in the design. Claims made through brand imagery are claims. Visual representations of mechanism of action are not neutral aesthetic choices. They carry regulatory implications that a generalist studio without life sciences experience will not recognize.
Include in the brief: the development stage, the target regulatory markets, and any specific communication restrictions the company's legal or regulatory affairs team has identified.
5. Naming and Naming Constraints
If the project involves company naming or renaming, the brief must address naming constraints explicitly. Biotech company names must satisfy multiple criteria simultaneously: they must be distinctive enough to trademark, scientifically appropriate for the category, globally usable across the markets the company operates in, and available as a domain name.
The brief should specify any naming conventions the company wants to follow or avoid, any existing trademark conflicts to work around, and the specific markets in which the name must function. For more on the naming criteria that work in life sciences, see my guide to biotech company naming.
6. Geographic Scope and Timeline
Biotech companies operate internationally from early stages. The brand must function across the US, EU, and in many cases Asian markets from the first application. Geographic scope affects naming availability, regulatory communication restrictions, and the cultural associations of visual language choices.
Timeline matters in biotech because development milestones create real branding events: a Series A requires investor-facing materials. A clinical trial start requires patient-facing materials. A regulatory filing requires a different kind of presentation. The brief should map the anticipated milestones against the branding deliverables needed for each.
7. What Success Looks Like
Most briefs describe what the brand should look like. The best briefs define what the brand should achieve. State the specific commercial or organizational outcomes the brand identity is intended to support: a Series A round, a partnership with a pharmaceutical company, a clinical trial recruitment campaign, a conference presence at a specific event. These success criteria determine whether the branding project worked.
What Most Studios Miss About Biotech Briefs
Most branding studios approach a biotech brief the way they approach any brand brief. They ask about tone of voice, audience, competitors, and visual references. They produce work that looks professional and communicates nothing specific about the science. The result is a brand that could belong to any of the 400 pre-clinical oncology companies founded in the last three years.
The gap is scientific literacy. A studio that cannot engage with the science cannot make the strategic decisions that differentiate a biotech brand. They will default to the visual conventions of the category (blue, clean, clinical, molecular imagery) because they do not have enough scientific context to know what would distinguish this company from that visual territory.
This is why biotech branding is a specialist capability. The brief you write can compensate for some of this gap by providing more scientific context than a standard brief includes. But it cannot fully replace the studio's ability to engage with that context and make strategic decisions from it.
For a full breakdown of what makes biotech branding different from consumer branding, see my guide to biotech branding.
The Biotech Branding Brief Template
Use this structure as a starting point:
Section | What to Include |
|---|---|
Company overview | What we do, in plain English. Development stage. Key scientific differentiation. |
Audience priority | Ranked list of audiences. What each needs to believe after brand exposure. |
Competitive landscape | 3-5 direct competitors. What their brands look like. Where we want to be different. |
Regulatory context | Target markets. Development stage. Communication restrictions from legal or regulatory. |
Naming brief (if applicable) | Naming conventions. Constraints. Global usability requirements. |
Geographic scope | Current markets. Target markets in 3-5 years. |
Deliverables | Specific brand assets required. Priority order. |
Timeline | Key milestones and when brand assets are needed for each. |
Success criteria | What commercial or organizational outcomes this brand should support. |
FAQ: Biotech Branding Brief
What should a biotech branding brief include?
A complete biotech branding brief includes a plain-English explanation of the science, a ranked list of audiences with what each needs to believe, a competitive landscape analysis, the regulatory context by market, naming constraints if applicable, geographic scope, the specific deliverables required, and the commercial or organizational outcomes the brand is intended to support.
Why is a biotech branding brief different from a standard brand brief?
A standard brand brief focuses on audience, tone, and aesthetic direction. A biotech brief must also explain the science in terms the studio can make strategic decisions from, define the regulatory communication restrictions that affect what can be said visually, distinguish between the investor, HCP, and patient audiences and what each requires, and specify the development stage milestones that create brand communication events.
How long should a biotech branding brief be?
A thorough biotech branding brief is typically 8 to 15 pages. It is longer than a consumer brand brief because the scientific context, regulatory landscape, and multi-audience requirements require more specification. A brief that fits on two pages has not covered the elements that make biotech branding different from any other category.
Should the founding team or an agency write the biotech branding brief?
The founding team should write the scientific and strategic sections: what the company does, why the science is different, what the regulatory restrictions are, and what success looks like. A branding studio may help write the competitive and audience sections as part of a paid discovery phase. The brief should not be written entirely by an agency without the founding team's scientific input.
What happens if a biotech branding brief is incomplete?
An incomplete brief produces generic work. A studio without sufficient scientific context defaults to category conventions. A brief without audience prioritization produces a brand optimized for no one. A brief without regulatory context produces claims and visual representations that require revision before any investor or HCP materials can be used.
I'm Tambi Haşpak, a brand strategist and creative director with an unfair advantage: I'm a pharmacist. I run a creative studio for life sciences, cosmetics, and supplements. 17 years. Exclusively. If you are preparing to brief a studio for your biotech brand and want to make sure the process produces work that earns trust and raises capital, book a call or send me an email.
